Medicine and Dentistry
Vasoactive Intestinal Polypeptide
100%
Patient with Inflammatory Bowel Disease
100%
Vaccine
100%
Antibody
62%
Infliximab
60%
Antibody Response
54%
COVID-19
50%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Case-Control Study
50%
T-Cell Response
50%
Mercaptopurine
46%
Inpatient
26%
Inflammatory Bowel Disease
21%
Ustekinumab
21%
Therapeutic Procedure
17%
Immunosuppressive Treatment
13%
Patient
12%
Infection
12%
Immunosuppressive Drug
12%
Protein Antibody
12%
Receptor Binding
9%
Diagnosis
9%
Age
8%
Immunology and Microbiology
Inflammatory Bowel Disease
100%
Vaccine Efficacy
100%
Infliximab
60%
Dose
58%
Antibody Response
54%
Monospecific Antibody
50%
COVID-19
50%
Severe Acute Respiratory Syndrome Coronavirus 2
45%
Tofacitinib
43%
Antibody Blood Level
34%
Spike
25%
Immunosuppressive Drug
21%
Vedolizumab
21%
Ustekinumab
21%
Tumor Necrosis Factor
13%
Protein Antibody
12%
Binding Antibody
9%
Receptor Binding
9%
Age
8%
Pharmacology, Toxicology and Pharmaceutical Science
Case-Control Study
50%
Inflammatory Bowel Disease
50%
Antibody
50%
Vaccine
50%
Vasoactive Intestinal Polypeptide
50%
Infliximab
37%
Mercaptopurine
33%
Tofacitinib
25%
SARS Coronavirus
25%
Ustekinumab
16%
Immunosuppressive Agent
12%
Infection
8%
mRNA Vaccine
8%